{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:23:54Z","timestamp":1792445034495,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.beem.2009.07.001","type":"journal-article","created":{"date-parts":[[2009,11,27]],"date-time":"2009-11-27T13:44:35Z","timestamp":1259329475000},"page":"735-751","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Amiodarone and thyroid"],"prefix":"10.1016","volume":"23","author":[{"given":"Silvia A.","family":"Eskes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilmar M.","family":"Wiersinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2009.07.001_bib1","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/FJC.0b013e31818914b6","article-title":"Amiodarone as paradigm for developing new drugs for atrial fibrillation","volume":"52","author":"Singh","year":"2008","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.beem.2009.07.001_bib2","series-title":"Pharmacotherapeutics of the thyroid gland","first-page":"225","article-title":"Amiodarone and the thyroid","author":"Wiersinga","year":"1997"},{"key":"10.1016\/j.beem.2009.07.001_bib3","first-page":"240","article-title":"The effects of amiodarone on the thyroid","volume":"22","author":"Martino","year":"2001","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.beem.2009.07.001_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000090725","article-title":"Effect of amiodarone on phospholipid content and composition in heart, lung, kidney and skeletal muscle: relationship to alteration in thyroid function","volume":"76","author":"Rabkin","year":"2006","journal-title":"Pharmacology"},{"key":"10.1016\/j.beem.2009.07.001_bib5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1089\/thy.2007.0215","article-title":"Amiodarone reversibly decreases sodium-iodide symporter mRNA expression at therapeutic concentrations and induces antioxidant responses at supraphysiological concentrations in cultured human thyroid follicles","volume":"17","author":"Yamazaki","year":"2007","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2009.07.001_bib6","series-title":"Thyroid and heart failure","first-page":"89","article-title":"Pharmacological effects of amiodarone and dronedarone on cardiac thyroid hormone receptors","author":"Wiersinga","year":"2009"},{"key":"10.1016\/j.beem.2009.07.001_bib7","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1210\/endo.134.4.8137729","article-title":"Desethylamiodarone is a noncompetitive inhibitor of the binding of thyroid hormone to the thyroid hormone \u03b21-receptor protein","volume":"134","author":"Bakker","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0303-7207(95)03578-U","article-title":"Desethylamiodarone is a competitive inhibitor of thyroid hormone binding to the thyroid hormone \u03b11-receptor","volume":"112","author":"Van Beeren","year":"1995","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0014-5793(99)00453-6","article-title":"Desethylamiodarone interferes with the binding of co-activitor GRIP to the \u03b21-thyroid hormone receptor","volume":"450","author":"Van Beeren","year":"1999","journal-title":"FEBS Letters"},{"key":"10.1016\/j.beem.2009.07.001_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/eje.0.1450059","article-title":"Desethylamiodarone antagonizes the effect of thyroid hormone at the molecular level","volume":"145","author":"Bogazzi","year":"2001","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pharmthera.2008.02.011","article-title":"Thyroid hormone and \u201ccardiac metamorphosis\u201d: potential therapeutic implications","volume":"118","author":"Pantos","year":"2008","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.beem.2009.07.001_bib12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.7326\/0003-4819-114-2-128","article-title":"An increase in plasma cholesterol independent of thyroid function during long-term amiodarone therapy. A dose-dependent relationship","volume":"114","author":"Wiersinga","year":"1991","journal-title":"Annales of Internal Medicine"},{"key":"10.1016\/j.beem.2009.07.001_bib13","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0026-0495(98)90277-3","article-title":"Amiodarone decreases gene expression of low-density lipoprotein receptor at both the mRNA and the protein level","volume":"47","author":"Hudig","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.beem.2009.07.001_bib14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/en.2002-220604","article-title":"Dronedarone acts as a selective inhibitor of 3,5,31-triiodothyronine binding to thyroid hormone receptor \u03b1: in vitro and in vivo evidence","volume":"144","author":"Van Beeren","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1210\/jcem-62-3-563","article-title":"Iodine kinetic studies during amiodarone treatment","volume":"62","author":"Rao","year":"1986","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2009.07.001_bib16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1210\/jcem-53-5-997","article-title":"Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration","volume":"53","author":"Melmed","year":"1981","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2009.07.001_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/hrt.79.2.121","article-title":"Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy","volume":"79","author":"Newman","year":"1998","journal-title":"Heart"},{"key":"10.1016\/j.beem.2009.07.001_bib18","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.amjmed.2004.11.028","article-title":"Amiodarone and the thyroid","volume":"118","author":"Basaria","year":"2005","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.beem.2009.07.001_bib19","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1365-2265.2008.03268.x","article-title":"Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists","volume":"69","author":"Tanda","year":"2008","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2265.2006.02590.x","article-title":"Management of amiodarone-induced thyrotoxicosis in Latin America: an electronic survey","volume":"65","author":"Diehl","year":"2006","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00045391-200607000-00007","article-title":"Incidence rate of adverse drug reactions during long-term follow-up of patients newly treated with amiodarone","volume":"13","author":"Bongard","year":"2006","journal-title":"American Journal of Therapeutics"},{"key":"10.1016\/j.beem.2009.07.001_bib22","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.amjmed.2007.04.022","article-title":"Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation","volume":"120","author":"Batcher","year":"2007","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.beem.2009.07.001_bib23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00508-008-1017-2","article-title":"Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism","volume":"120","author":"Hofmann","year":"2008","journal-title":"Wiener Klinische Wochenschrift"},{"key":"10.1016\/j.beem.2009.07.001_bib24","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1001\/archinte.160.12.1741","article-title":"Practical guidelines for clinicians who treat patients with amiodarone","volume":"160","author":"Goldschlager","year":"2000","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.beem.2009.07.001_bib25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clpt.2003.09.010","article-title":"Monitoring amiodarone's toxicities: recommendations, evidence, and clinical practice","volume":"75","author":"Stelfox","year":"2004","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.beem.2009.07.001_bib26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0002-9343(91)90187-3","article-title":"Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism","volume":"91","author":"Trip","year":"1991","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.beem.2009.07.001_bib27","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1445-5994.2006.01068.x","article-title":"Monitoring the use of amiodarone: compliance with guidelines","volume":"36","author":"Burgess","year":"2006","journal-title":"Internal Medicine Journal"},{"key":"10.1016\/j.beem.2009.07.001_bib28","doi-asserted-by":"crossref","first-page":"254","DOI":"10.18553\/jmcp.2006.12.3.254","article-title":"Adherence to the NASPE guideline for amiodarone monitoring at a medical university","volume":"12","author":"Bickford","year":"2006","journal-title":"Journal of Managed Care Pharmacy"},{"key":"10.1016\/j.beem.2009.07.001_bib29","doi-asserted-by":"crossref","first-page":"656","DOI":"10.18553\/jmcp.2006.12.8.656","article-title":"Liver and thyroid monitoring in ambulatory patients prescribed amiodarone in 10 HMOs","volume":"12","author":"Raebel","year":"2006","journal-title":"Journal of Managed Care Pharmacy"},{"key":"10.1016\/j.beem.2009.07.001_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/BF03346400","article-title":"Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy","volume":"31","author":"Bogazzi","year":"2008","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.beem.2009.07.001_bib31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/jcem-63-2-485","article-title":"Uninhibited thyroidal uptake of radioiodine despite iodine excess in amiodarone-induced hypothyroidism","volume":"63","author":"Wiersinga","year":"1986","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2009.07.001_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/eje.0.1400241","article-title":"Amiodarone compared with iodine exhibits a potent and persistent inhibitory effect on TSH-stimulated cAMP production in vivo: a possible mechanism to explain amiodarone-induced hypothyroidism","volume":"140","author":"Pitsiavas","year":"1999","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib33","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1210\/en.2005-1246","article-title":"Amiodarone inhibits thyroidal iodide transport in vitro by a cyclic adenosine 51-monophosphate- and iodine-independent mechanism","volume":"147","author":"Tedelind","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib34","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1210\/jcem-63-5-1233","article-title":"Short term administration of potassium perchlorate restores euthyroidism in amiodarone iodine-induced hypothyroidism","volume":"63","author":"Martino","year":"1986","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2009.07.001_bib35","first-page":"21","article-title":"Treatment of amiodarone-induced hypothyroidism with potassium perchlorate","volume":"42","author":"Van Dam","year":"1993","journal-title":"The Netherlands Journal of Medicine"},{"key":"10.1016\/j.beem.2009.07.001_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-198301000-00001","article-title":"Iodide-induced thyrotoxicosis","volume":"62","author":"Fradkin","year":"1983","journal-title":"Medicine"},{"key":"10.1016\/j.beem.2009.07.001_bib37","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1210\/endo.134.5.8156930","article-title":"Studies on the in vitro cytotoxic effect of amiodarone","volume":"134","author":"Chiovato","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/eje.0.1370089","article-title":"Amiodarone induces a different pattern of ultrastructural change in the thyroid to iodine excess alone in both the BB\/W rat and the Wistar rat","volume":"137","author":"Pitsiavas","year":"1997","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/eje.0.1370015","article-title":"Towards an animal model of amiodarone-induced thyroid dysfunction","volume":"137","author":"Wiersinga","year":"1997","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00000478-198703000-00004","article-title":"Pathology of the thyroid in amiodarone-associated thyrotoxicosis","volume":"11","author":"Smyrk","year":"1987","journal-title":"The American Journal of Surgical Pathology"},{"key":"10.1016\/j.beem.2009.07.001_bib41","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.1995.5.177","article-title":"Nongoitrous (type II) amiodarone-associated thyrotoxicosis: evidence of follicular disruption in vitro and in vivo","volume":"5","author":"Brennan","year":"1995","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2009.07.001_bib42","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/BF03344178","article-title":"Long-term outcome of thyroid function after amiodarone-induced thyrotoxicosis, as compared to subacute thyroiditis","volume":"29","author":"Bogazzi","year":"2006","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/j.beem.2009.07.001_bib43","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-2265.2007.02920.x","article-title":"Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy","volume":"67","author":"Bogazzi","year":"2007","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib44","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/eje.1.02122","article-title":"Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality","volume":"154","author":"O'Sullivan","year":"2006","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib45","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2007.02.054","article-title":"Amiodarone-induced thyrotoxicosis. Clinical course and predictors of outcome","volume":"49","author":"Conen","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1016\/j.beem.2009.07.001_bib46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2165\/00044011-200828080-00008","article-title":"Atrial fibrillation due to late amiodarone-induced thyrotoxicosis","volume":"28","author":"Kurt","year":"2008","journal-title":"Clinical Drug Investigation"},{"key":"10.1016\/j.beem.2009.07.001_bib47","first-page":"423","article-title":"Serum IL-6 in amiodarone-induced thyrotoxicosis","volume":"78","author":"Bartalena","year":"1994","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2009.07.001_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1210\/jcem.86.1.7119","article-title":"Amiodarone-induced thyrotoxicosis","volume":"86","author":"Daniels","year":"2001","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2009.07.001_bib49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.0300-0664.2001.01457.x","article-title":"Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography","volume":"56","author":"Eaton","year":"2002","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1089\/105072503321319521","article-title":"Ba\u015fkal N, Erdogan G. A stepwise approach to the treatment of amiodarone-induced thyrotoxicosis","volume":"13","author":"Erdogan","year":"2003","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2009.07.001_bib51","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1089\/105072503322239989","article-title":"The prevalence of elevated serum C-reactive protein levels in inflammatory and noninflammatory thyroid disease","volume":"13","author":"Pearce","year":"2003","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2009.07.001_bib52","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/thy.1997.7.541","article-title":"Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis","volume":"7","author":"Bogazzi","year":"1997","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2009.07.001_bib53","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1080\/02841850701342138","article-title":"Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis","volume":"48","author":"Loy","year":"2007","journal-title":"Acta Radiologica"},{"key":"10.1016\/j.beem.2009.07.001_bib54","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1080\/02841850701280791","article-title":"Differentiation between the two types of amiodarone-associated thyrotoxicosis using duplex and amplitude Doppler sonography","volume":"48","author":"Macedo","year":"2007","journal-title":"Acta Radiologica"},{"key":"10.1016\/j.beem.2009.07.001_bib55","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1530\/EJE-08-0348","article-title":"The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis","volume":"159","author":"Piga","year":"2008","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/01.md.0000123095.65294.34","article-title":"Complex drug-drug-disease interactions between amiodarone, warfarin, and the thyroid gland","volume":"83","author":"Kuzaik","year":"2004","journal-title":"Medicine"},{"key":"10.1016\/j.beem.2009.07.001_bib57","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1136\/hrt.72.3.266","article-title":"Two cases of amiodarone-induced thyrotoxicosis successfully treated with a short course of antithyroid drugs while amiodarone was continued","volume":"72","author":"Trip","year":"1994","journal-title":"British Heart Journal"},{"key":"10.1016\/j.beem.2009.07.001_bib58","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0002-9343(97)00047-8","article-title":"Lithium treatment in amiodarone-induced thyrotoxicosis","volume":"102","author":"Dickstein","year":"1997","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.beem.2009.07.001_bib59","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1210\/jc.2002-021874","article-title":"Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study","volume":"88","author":"Bogazzi","year":"2003","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2009.07.001_bib60","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00268-004-7599-6","article-title":"Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience","volume":"28","author":"Houghton","year":"2004","journal-title":"World Journal of Surgery"},{"key":"10.1016\/j.beem.2009.07.001_bib61","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1007\/s00268-005-0673-x","article-title":"Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac disease","volume":"30","author":"Gough","year":"2006","journal-title":"World Journal of Surgery"},{"key":"10.1016\/j.beem.2009.07.001_bib62","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00423-006-0112-y","article-title":"Combination of minimally invasive thyroid surgery and local anaesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study","volume":"392","author":"Berti","year":"2007","journal-title":"Langenbecks Archive Surgery"},{"key":"10.1016\/j.beem.2009.07.001_bib63","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1365-2265.2008.03405.x","article-title":"Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis (AIT)","volume":"70","author":"Albino","year":"2009","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib64","article-title":"Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: a cautionary note","author":"Bogazzi","year":"2009","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib65","first-page":"706","article-title":"Radioactive iodine in the treatment of type 2 amiodarone-induced thyrotoxicosis","volume":"100","author":"Gursoy","year":"2008","journal-title":"Journal of the National Medical Association"},{"key":"10.1016\/j.beem.2009.07.001_bib66","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1161\/circ.105.11.1275","article-title":"Successful treatment of amiodarone-induced thyrotoxicosis","volume":"105","author":"Osman","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2009.07.001_bib67","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00002018-200629030-00006","article-title":"Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis","volume":"29","author":"Uzan","year":"2006","journal-title":"Drug Safety"},{"key":"10.1016\/j.beem.2009.07.001_bib68","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/ncpendmet0592","article-title":"Treatment of amiodarone-associated thyrotoxicosis","volume":"3","author":"Franklyn","year":"2007","journal-title":"Nature Clinical Practice. Endocrinology & Metabolism"},{"key":"10.1016\/j.beem.2009.07.001_bib69","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1210\/jc.2006-2059","article-title":"Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroditis is predicted by thyroid volume and serum free thyroid hormone concentrations","volume":"92","author":"Bogazzi","year":"2007","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2009.07.001_bib70","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2265.2008.03350.x","article-title":"Benzofuran derivatives and the thyroid","volume":"70","author":"Han","year":"2009","journal-title":"Clinical Endocrinology"},{"key":"10.1016\/j.beem.2009.07.001_bib71","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1089\/105072504322880391","article-title":"Can amiodarone be restarted after amiodarone-induced thyrotoxicosis?","volume":"14","author":"Ryan","year":"2004","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2009.07.001_bib72","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1507\/endocrj.K06-027","article-title":"Mild and short recurrence of type II amiodarone-induced thyrotoxicosis in three patients receiving amiodarone continuously for more than 10 years","volume":"53","author":"Sato","year":"2006","journal-title":"Endocrine Journal"},{"key":"10.1016\/j.beem.2009.07.001_bib73","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1210\/jc.2008-1907","article-title":"Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome","volume":"94","author":"Yiu","year":"2009","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2009.07.001_bib74","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/BF03343825","article-title":"Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment","volume":"24","author":"Bartalena","year":"2001","journal-title":"Journal of Endocrinological Investigation"},{"issue":"S2","key":"10.1016\/j.beem.2009.07.001_bib75","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1540-8167.2006.00583.x","article-title":"Dronedarone: an emerging agent with rhythm- and rate-controlling effects","volume":"17","author":"Wegener","year":"2006","journal-title":"Journal of Cardiovascular Electrophysiology"},{"key":"10.1016\/j.beem.2009.07.001_bib76","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/thy.2005.15.16","article-title":"Dronedarone administration prevents body weight gain and increases tolerance of the heart to ischemic stress: a possible involvement of thyroid hormone receptor \u03b11","volume":"15","author":"Pantos","year":"2005","journal-title":"Thyroid"},{"key":"10.1016\/j.beem.2009.07.001_bib77","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa054686","article-title":"Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter","volume":"357","author":"Singh","year":"2007","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2009.07.001_bib78","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1056\/NEJMoa0803778","article-title":"Effect of dronedarone on cardiovascular events in atrial fibrillation","volume":"360","author":"Hohnloser","year":"2009","journal-title":"The New England Journal of Medicine"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X09000773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X09000773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:41:58Z","timestamp":1761496918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X09000773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S1521690X09000773"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2009.07.001","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amiodarone and thyroid","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2009.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}